Endocrine Abstracts (2004) 7 P117

Managing prolactinomas: our experience at Preston

M Banerjee1, M Myers2 & PA Vice1


1Endocrine Unit, Department of Medicine, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Lancashire, UK; 2Department of Clinical Biochemistry, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Lancashire, UK.


Patients who have Sr. Prolactin level >3000 mU/l (n=24) were selected from the Biochemistry laboratory record & patients with confirmed diagnosis of prolactinoma (n=33) identified and / followed up at Endocrine Clinic between December 1999 and October 2001 were studied. The mean age of the patients were 45.03+ 14.09 years and 72% were women. Of the patients diagnosed to have prolactinoma, 16 had microprolactinoma. 16 had macroprolactinoma and 1 had stalk disconnection. Of 24 who had incidental elevated prolactin, 10 were reported to have normal level, 7 elevated level (all were on psychotropic drugs) on repeat check and in the other 7 no further checks were done. Initial IST, TRH and LRH tests were done in 87% of macroprolactinomas, while they were done in 60% of microprolactinomas.14 patients with macroprolactinoma had extrasellar extension initially, which persisted in 2 patients during follow up. Visual fields were tested in 94% of macroprolactinoma patients and were found to be normal in 47% of them.

50% of macroprolactinoma patients were managed by dopamine agonists only, 37.5% by hypophysectomy and 12.5% by hypophysectomy and radiotherapy. 94% of microprolctinoma patients were managed with dopamine agonists only but 1 patient required hypophysectomy who subsequently has iatrogenic hypopituitarism.

After therapy, the visual field abnormalities resolved in 75% of patients, while the rest had persistent but no worsening of symptoms. 50% of macroprolactinoma patients are not on any hormone replacement at the follow up phase. 85.96% of patients achieved biochemical cure and 37.5% of patients achieved radiological resolution. Only 28.13% of all patients developed iatrogenic hypopituitarism. 15 living patients with macroprolactinoma and 13 patients with microprolactinoma are still being actively followed up at Preston.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts